Pfizer Reports Top-Line Results From Second Pivotal Phase 3 Study Of Abrocitinib In Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis: Achieved Co-Primary, Key Secondary Endpoints
Benzinga Newsdesk